MitoQ
MitoQ (mitoquinone mesylate), mitochondria-targeted antioxidant
Written by Aaron CuhaReviewed Sep 2026
Also known as: Mitoquinone, Mitoquinone mesylate, MitoQ10
A widely sold mitochondrial antioxidant that failed mouse lifespan testing, and that did improve vascular function in a randomised trial of 20 healthy older adults.
Overview
MitoQ is the most commercially successful mitochondria-targeted antioxidant, and its evidence splits cleanly in a way its marketing does not.
On lifespan, it failed. It went through the Interventions Testing Program and produced no significant lifespan effect in either sex. That is the relevant answer to the claim that targeting mitochondrial oxidative damage slows ageing.
On vascular function, it has a real randomised human result. A trial in healthy older adults found improved endothelial function after six weeks of supplementation, published in a good journal. It is a small trial with a surrogate endpoint, and it is genuine randomised human evidence, which is more than most supplements in this category have.
Both halves belong on the page. A product can improve a measurable function and not extend life.
Mechanism of action
A ubiquinone moiety, the same redox-active head group as coenzyme Q10, covalently attached to a triphenylphosphonium cation. That lipophilic cation accumulates several hundred-fold inside mitochondria, driven by the negative membrane potential across the inner membrane. So unlike ordinary antioxidants, which distribute broadly, MitoQ concentrates where mitochondrial superoxide is produced. Note that it is not a coenzyme Q10 substitute: it does not participate in the respiratory chain as an electron carrier, because the targeting group interferes with that role.
Human evidence
One randomised placebo-controlled trial in healthy older adults with a positive vascular function result, plus scattered smaller work. No lifespan or clinical event data in people.
- Randomised placebo-controlled supplementation in healthy older adults improved vascular function.
- The endpoint is endothelial and vascular physiology, not blood pressure outcomes, cardiovascular events or mortality.
- The trial is small, which limits precision and means the effect size should be read with caution.
- No human trial has examined lifespan, healthspan, cognition or any hard clinical endpoint.
- Separately, the compound produced no significant lifespan effect in multi-site mouse testing.
What this does not tell you: The vascular result is real randomised evidence and it is one small trial measuring a surrogate. Improved endothelial function predicts cardiovascular risk; it is not the same as fewer heart attacks, and nobody has tested that here. The lifespan null is the direct test of the ageing claim, and it was negative. Do not read the vascular finding as support for the longevity claim; they are different questions with different answers.
Reading the research record
MitoQ is a good case study in how a compound can be simultaneously better and worse than its reputation. The mitochondrial free radical theory of ageing, which motivated it, has weakened considerably: general antioxidant supplementation has repeatedly failed to extend life and sometimes shortened it, and this compound's own lifespan null fits that pattern.
At the same time, this is not one of the many supplements with nothing but cell culture behind it. Somebody ran a randomised placebo-controlled trial in older adults and measured a vascular improvement. That deserves to be reported as what it is: a real finding on a surrogate endpoint, in a small sample, about a different question from lifespan.
The Interventions Testing Program is run by the National Institute on Aging at three independent sites, The Jackson Laboratory, the University of Michigan and the University of Texas Health Science Center at San Antonio. It uses UM-HET3 mice, a genetically heterogeneous four-way cross, so a result cannot be an artefact of one inbred strain. Compounds are fed in the diet, both sexes are tested, cohorts are large enough to detect roughly a 10 percent lifespan change, and results are analysed by log-rank for median survival and by the Wang-Allison test for maximum lifespan. Its nulls are published alongside its positives. That combination of features does not exist anywhere else in ageing research, which is why a null here means considerably more than a null from a single laboratory.
The evidence, charted
Fig. 1 · evidence composition
1of 2 citations (50%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Citations here span just two years, 2018 and 2024.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Human2018
Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults
A randomised placebo-controlled trial in healthy older adults reporting improved vascular function after chronic MitoQ supplementation. This is the strongest human result for the compound, it is small, and the endpoint is a physiological measure rather than a clinical event.
Hypertension - Animal2024
Targeting mitochondrial dysfunction using methylene blue or mitoquinone to improve skeletal aging
Animal work examining whether mitochondria-targeted agents improve skeletal ageing, covering both mitoquinone and methylene blue. Included because bone is a tissue where mitochondrial ageing has a plausible and separately testable role.
Aging
Frequently asked questions
Does MitoQ extend lifespan?
No. It produced no significant lifespan effect in either sex in multi-site mouse testing, which is the most rigorous lifespan test available. No human lifespan data exists for it or for anything else in this category.
So is the vascular finding worthless?
No, and it is worth being precise. A randomised placebo-controlled trial in healthy older adults found improved vascular function. That is genuine human evidence for a specific physiological effect. It is a small trial with a surrogate endpoint, and it says nothing about lifespan.
Is MitoQ the same as CoQ10?
No. It shares the redox head group but carries a targeting cation that concentrates it inside mitochondria and prevents it acting as an electron carrier in the respiratory chain. So it is not a CoQ10 substitute, and CoQ10's one strong outcome trial in heart failure does not transfer to it.
Why did a mitochondrial antioxidant fail if oxidative damage causes ageing?
Because that premise is weaker than it sounds. Antioxidant supplementation has repeatedly failed to extend lifespan, and there is evidence that some reactive oxygen signalling is necessary for adaptive responses, including to exercise. Suppressing it may remove a signal rather than a cause.